Bruker Corporation and NovAliX collaborated strategically to develop novel drug discovery technologies and methods, with the goal of enabling new paradigms in leveraging biophysical methods for drug discovery. The companies will partner on advancing functional structural biology, biophysical methods for characterizing molecular dynamics and interactions, biocondensates and aggregation, drug candidate binding, therapeutic mechanisms of action (MoA), and elucidating potential off-target effects. The overarching objectives are to discover new or improved targets, as well as new drug modalities or optimized drug candidates, and to predict drug discovery failures earlier.

NovAliX will benefit from Bruker?s unique technologies in innovative high-end biophysical characterization methods, particularly NMR, but also leveraging biosensors, mass spectrometry, single-cell and spatial biology tools, to advance NovAliX services for discovery and development of new medicines even faster. NovAliX excels in drug discovery, combining biophysics, medicinal chemistry, and pharmacology, and is home to award-winning scientists who have invented drugs that are benefiting patients today. Their advanced biophysics platform supports drug discovery from target assessment to lead optimization.

NovAliX partnerships, e.g., with the Max Planck Institute in Cryo-EM, or on a unique DNA-Encoded Library (DEL) platform, highlight their commitment to advancing drug discovery through technology and strategic alliances. Bruker?s partnership with NovAliX will enable both companies to accelerate the development, incubation, deployment and support for advanced biophysical methods, leveraging Bruker?s leading post-genomic solutions competencies, combined with NovAliX?s expert services and innovation. Anticipated areas of joint innovation in drug discovery methods include, for example: Ultra-high field NMR functional structural and binding investigations on protein and RNA structures and complexes, as well as on novel therapeutic peptides and oligonucleotides; NMR-powered medicinal chemistry, structure-activity relationships (SAR) and MoA research; Biologics and new drug modalities higher-order structure confirmation, similarity assessment and QC by NMR; Unique NMR studies of intrinsically disordered proteins or regions (IDPs/IDRs) for condensate biology in drug discovery and condensate cell biology studies; X-ray crystallography for structure-guided drug discovery; High sensitivity, high-throughput SPR for kinetics, affinity, and binding studies; High-performance MS for proteomics, multiomics, glycobiology, native MS and proteoforms; and Single cell and spatial biology tools for cell and tissue heterogeneity insights for drug discovery.

Looking ahead, Bruker and NovAliX also plan to conduct joint innovation activities through the Biophysics Institute for Biomedical Research (IBRB) in Strasbourg. This new institute, set to open in 2026, will host biotechs, start-ups, and academic groups, fostering collaboration and innovation in the field of biophysics and drug discovery.